Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques

Vaccine

Volumn 24, Issue 23, 2006, Pages 5064-5072

  Gómez Román, V Raúl ^a   Grimes Jr , George J ^b   Potti, Gopal K ^b   Peng, Bo ^a   Demberg, Thorsten ^a   Gravlin, Luisa ^b   Treece, James ^c   Pal, Ranajit ^c   Lee, Eun Mi ^c   Alvord, W Gregory ^d   Markham, Phillip D ^c   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Replication competent adenovirus vectors; Rhesus macaque; SIV SHIV

Indexed keywords

ADENOVIRUS VECTOR; DRUG CARRIER; POLYVINYL ACETATE; STEARIC ACID; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO; ENTERIC COATED TABLET; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; UPPER RESPIRATORY TRACT; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

ADENOVIRUSES, HUMAN; ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; BODY TEMPERATURE; CD4 LYMPHOCYTE COUNT; GENETIC VECTORS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIREMIA; VIRUS REPLICATION;

EID: 33646884133     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.048     Document Type: Article

References (44)

1. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71 (1997) 8531-8541
2. Buge S.L., Murty L., Arora K., Kalyanaraman V.S., Markham P.D., Richardson E.S., et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 73 (1999) 7430-7440 (Erratum: J Virol 1999;73:9692)
3. Zhao J., Lou Y., Pinczewski J., Malkevitch N., Aldrich K., Kalyanaraman V.S., et al. Boosting of SIV-specific cellular immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and SIVgag recombinants. Vaccine 21 (2003) 4022-4035
4. Malkevitch N., Patterson L.J., Aldrich K., Richardson E., Alvord W.G., and Robert-Guroff M. A replication competent Ad5hr-SIV recombinant priming/subunit boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity in Mamu-A*01 rhesus macaques. J Immunol 170 (2003) 4281-4289
5. Patterson L.J., Malkevitch N., Pinczewski J., Venzon D., Lou Y., Peng B., et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 77 (2003) 8607-8620
6. mac251 intrarectal challenge following Ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol 18 (2005) 236-243
7. 251. J Immunol 174 (2005) 2185-2189
8. mac251 challenge by a replication competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 77 (2003) 8354-8365
9. Patterson J.L., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIVmac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 (2004) 2212-2221
10. Natuk R.J., Lubeck M.D., Chanda P.K., Chengalvala M., Wade M.S., Murthy S.C.S., et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 9 (1993) 303-395
11. Lubeck M.D., Natuk R.J., Chengalvala M., Chanda P.K., Murthy K.K., Murthy S., et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 10 (1994) 1443-1449
12. Lubeck M.D., Natuk R.J., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med 3 (1997) 651-658
13. Zolla-Pazner S., Lubeck M., Xu S., Burda S., Natuk R.J., Sinangil F., et al. Induction of neutralizing antibodies in chimpanzees to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime/boost vaccine regimen in chimpanzees. J Virol 72 (1998) 1052-1059
14. Robert-Guroff M., Kaur H., Patterson L.J., Leno M., Conley A.J., McKenna P.M., et al. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol 72 (1998) 10275-10280
15. Peng B., Wang L.R., Gomez-Roman V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79 (2005) 10200-10209
16. Malkevitch N.V., and Robert-Guroff M. A call for replicating vector prime/protein boost strategies in HIV vaccine design. Exp Rev Vaccines Suppl 3 (2004) 89-101
17. Rubin B.A., and Rorke L.B. Adenovirus vaccines. In: Plotkin S.A., and Mortimer Jr. E.A. (Eds). Vaccines (1988), W.B. Saunders Company, Philadelphia 492-512
18. Gaydos C.A., and Gaydos J.C. Adenovirus vaccines in the U.S. military. Mil Med 160 (1995) 300-304
19. Horwitz M.S., and Adenoviruses. In: Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Melnick J.L., Monath T.P., et al. (Eds). Fields virology. 3rd ed. vol. 2 (1996), Lippincott-Raven Publishers, Philadelphia 2149-2171
20. Ginsberg H.S., Lundholm-Beauchamp U., Horswood R.L., Pernis B., Wold W.S.M., Chanock R.M., et al. Role of early region 3 (E3) in pathogenesis of denovirus disease. Proc Natl Acad Sci USA 86 (1989) 3823-3827
21. Patterson L.J., Prince G.A., Richardson E., Alvord W.G., Kalyan N., and Robert-Guroff M. Insertion of HIV-1 genes into Ad4ΔE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 292 (2002) 107-113
22. Berencsi K., Uri A., Valyi-Nagy T., Valyi-Nagy I., Meignier B., Peretz F.V., et al. Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses. Lab Invest 71 (1994) 350-358
23. Croyle M.A., Cheng X., and Wilson J.M. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 8 (2001) 1281-1290
24. Chengalvala M., Lubeck M.D., Davis A.R., Mizutani S., Molner-Kimber J., Morin J., et al. Evaluation of adenovirus type 4 and 7 recombinant hepatitis B vaccines in dogs. Vaccine 9 (1991) 485-489
25. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Meth 86 (2000) 61-70
26. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS system for mixed models (1996), SAS Institute Inc.
27. Milliken G.A., and Johnson D.E. Analysis of messy data, designed experiments vol. 1 (1992), Chapman and Hall, New York
28. Pinheiro J.C., and Bates D.M. Mixed-effects models in S and S-plus (2000), Springer-Verlag, New York
29. Levine M.M., and Campbell J.D. Mucosal immunization and needle-free infection devices. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Mood M.F. (Eds). New generation vaccines. 3rd ed. (2004), Barcel Dekker Inc., New York 393-399
30. Payne A.M. Oral immunization against poliomyelitis. Bull WHO 23 (1960) 695-703
31. Melnick J.L. Problems associated with the use of live poliovirus vaccine. Am J Public Health 50 (1960) 1013-1031
32. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., and Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17 Suppl 2 (1999) S22-S27
33. Cryz Jr. S.J., Kaper J., Tacket C., Nataro J., and Levine M.M. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction safety, immunogenicity, excretion and non-target effects. Dev Biol Stand 84 (1995) 237-244
34. Chanock R.M., Ludwig W., Heubner R.J., Cate T.R., and Chu L.W. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 195 (1966) 445-452
35. Edmondson W.P., Purcell R.H., Gundelfinger B.R., Love J.W., Ludwig W., and Chanock R.M. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. Specific protective effect against epidemic disease. JAMA 195 (1966) 453-459
36. Gutekunst R.R.M., White R.J., Edmondson W.P., and Chanock R.M. Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol 86 (1967) 341-349
37. Mueller R.E., Muldoon R.L., and Jackson G.G. Communicability of enteric live adenovirus type 4 vaccine in families. J Infect Dis 119 (1969) 60-66
38. Stanley E.D., and Jackson G.G. Spread of enteric live adenovirus type 4 vaccine in married couples. J Infect Dis 119 (1969) 51-59
39. Takafuji E.T., Gaydos J.C., Allen R.G., and Top Jr. F.H. Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines: safety and immunogenicity. J Infect Dis 140 (1979) 48-53
40. Top Jr. F.H., Grossman R.A., Bartelloni P.J., Segal H.E., Dudding B.A., Russell P.K., et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis 124 (1971) 148-154
41. Smith T.J., Buescher E.L., Top Jr. F.H., Altemeier W.A., and McCown J.M. Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses. J Infect Dis 122 (1970) 239-248
42. Hel Z., Nacsa J., Tryniszewska E., Tsai W.-P., Parks R.W., Montefiori D.C., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169 (2002) 4778-4787
43. Hel Z., Nacsa J., Tsai W.-P., Thornton A., Giuliani L., Tartaglia J., et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304 (2002) 125-134
44. 251 infection of macaques. Nature Med 6 (2000) 1140-1146